Casey McDonald

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.

Cleveland Clinic looks at the big medical innovations in store for 2017.

The industry is readying for a leap into a new age of complex therapies, as new heights are reached in fields such as regenerative cell-based therapies, CAR-T and immuno-oncology combinations. Elaborate manufacturing and soaring drug costs, however, loom as deep chasms to cross in bridging the potential with reality.

Today’s C-suite executives in the life sciences must be experts in many disciplines. Pharm Exec examines the evolving role of the chief financial officer as not just a numbers and bottom-line risk manager but an integral contributor to overall corporate strategy and close partner to the CEO.

When lobbying tips the scales: a path to drug approval.

Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation

Vice President, US Payer & Institutional Strategy Lead, Shire

Vice President, Business Development, Regeneron Pharmaceuticals

Senior Director, Marketing, XenoPort

Pharm Exec convenes some of the industry’s top business development professionals and negotiators to talk about the current climate for biophamara dealmaking and the critical job of appraising new assets and their potential as market-worthy and transformative products for patients.

Pharm Exec adds up some interesting figures from recent industry news.

A new wave of technologies supported by innovative business models is transforming the vaccine landscape - and raising the bar on performance. As the demand for cures for chronic diseases accelerates, and with more global outbreaks of viral diseases like Zika and Ebola a virtual certainty, solutions can’t come soon enough.

As Mr Shkreli goes to Washington, Casey McDonald considers what the silver screen treatment of this chapter in the pharma bro saga might be like.

It’s easy to foresee controversy in 2016 as lagging global economic growth and a messy US political slugfest force the pharma industry’s feet to the fire. Can the industry reclaim a semblance of public approval by confronting its pricing demons and focusing on innovation and a fresh, patient-first message?

Casey McDonald keeps an eye on the one of the healthcare industry’s biggest weeks on Twitter with regular updates here.

January 08, 2016.

Cures remain elusive, but regulators and industry are building ties that bind.

The All-Star CEO panel last week’s Forbes Healthcare Summit was overshadowed by Matthew Herper’s interview with industry’s leading villain, Martin Shkreli, showing that drug pricing is still the leading topic on everyone’s minds.

Rare disease supporters deliver inspiration and optimism-as well as promise of regulatory cooperation.

Prix Galien USA had its day, a fall tradition bringing the celebs of the biopharma industry to New York City for discussion and debate and a night of glitz. Casey McDonald reports.

The Alliance for Clinical Research Excellence and Safety (ACRES) is advocating a “systems thinking” approach in efforts to meet increasing demands to standardize and integrate support for trial sites.

Casey McDonald previews pharma’s Oscars, the Prix Galien USA Awards, which this fall will bring some red carpet glamor and, hopefully, cheer to the industry.

September 28, 2015.

A slightly different take on this Turing Pharmaceuticals/Martin Shkreli business?

UNITE HERE, a labor union representing 270,000 workers people across Canada and the US, is has questioned pharma’s connections to the influential and highly visible American Heart Association (AHA). Casey McDonald reports.

September 16, 2015.

Free speech ruling, social media flap, and "female Viagra" highlight busy month for agency.

The American Medical Association invested heavily in DC influence in the first two quarters of 2015. PhRMA wasn't far behind. Casey McDonald reports.

Amgen and Sandoz received a decision from the U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday. PharmExec spoke with legal and biosimilar experts for their initial reactions.